Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
9Customers
2Debt Items
9Related Chains
Source-Backed Evidence Depth
Rhythm Pharmaceuticals, Inc. (RYTM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
2Distinct source URLs
8High confidence
0.769Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Rhythm Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CMOS
CMOS
85%
To meet our projected needs for clinical supplies to support our activities through regulatory approval and commercial manufacturing, the CMOs with whom we currently work may need to increase scale o…
GENETIC-TESTING-SERVICE-PROVIDERS
GENETIC-TESTING-SERVICE-PROVIDERS
85%
The Company relies on separate third parties to perform genetic testing in the United States and Europe, respectively.
Reciprocal relationship from PHVS graph: Reciprocal relationship from RYTM graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from RYTM graph: Reciprocal relationship from PHVS g…
Rhythm Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
SINGLE-CUSTOMER-IN-THE-UNITED-STATES
SINGLE-CUSTOMER-IN-THE-UNITED-STATES
92%
For the three months ended March 31, 2026, and 2025, approximately 61 % and 65 % of all the Company’s revenue was generated from a single customer in the United States.
SINGLE-INTERNATIONAL-CUSTOMER
SINGLE-INTERNATIONAL-CUSTOMER
92%
Additionally, a single international customer also generated approximately 12 % of the Company's revenue during the three months ended March 31, 2026.
CMOS-POLYPEPTIDE-GROUP
CMOS-POLYPEPTIDE-GROUP
85%
in the future. We have entered into process development and manufacturing service agreements with our CMOs, PolyPeptide Group, Braine L'Alleud, or Polypeptide, Neuland Laboratories, and Astrea Monts …
ALEXION-PHARMACEUTICALS-INC
ALEXION-PHARMACEUTICALS-INC
62%
ial commercialization of a product candidate for CHI. In addition, since we have market access for IMCIVREE for BBS or POMC and LEPR deficiencies, or both, in more than 15 countries outside of the Un…
HEALTHCARE-ROYALTY-MANAGEMENT-LLC
HEALTHCARE-ROYALTY-MANAGEMENT-LLC
62%
y and RareStone, dated December 3, 2021 (the “Share Purchase Agreement”, and with the License Agreement the “RareStone Agreements”). Under the Termination Agreement, the Company agreed to pay $ 6.3 m…
LG-CHEM-LTD
LG-CHEM-LTD
62%
etmelanotide. We first commercialized IMCIVREE in the United States in the first quarter of 2021 and therefore do not have a long history operating as a commercial company. We are continuing to trans…
PERCEPTIVE-ADVISORS-LLC
PERCEPTIVE-ADVISORS-LLC
62%
ion cost of $ 51,615 related to non-vested employee restricted stock unit and performance stock unit awards under all equity plans that are expected to be recognized over a weighted-average period of…
RARESTONE-GROUP-LTD
RARESTONE-GROUP-LTD
62%
not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect lic…
RHYTHM-HOLDINGS-LLC
RHYTHM-HOLDINGS-LLC
62%
etmelanotide. We first commercialized IMCIVREE in the United States in the first quarter of 2021 and therefore do not have a long history operating as a commercial company. We are continuing to trans…
Rhythm Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RYTM-DEBT
Debt stack $106.1M
90%
Market cache reports total debt of $106.1M.
RYTM-DEBT-12337
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Rhythm Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Rhythm Pharmaceuticals, Inc..
Rhythm Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
RYTM-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 288 tracked holders.
Rhythm Pharmaceuticals, Inc. Extended Supply Chain Network
